CP202

CP202 is a preclinical-stage small molecule drug candidate being developed by Guangzhou Cellprotek Pharmaceutical for the treatment of Alzheimer's disease (AD). Designed for oral administration, the compound employs a multi-targeted approach to address the complex pathology of neurodegeneration. Reported pharmacological actions include the enhancement of cerebral blood flow, reduction of neuroinflammation, and the lowering of key Alzheimer's biomarkers, specifically amyloid-beta (Aβ) and tau proteins. Additionally, CP202 has demonstrated the ability to reduce lipid accumulation, improve cognitive function, and modulate neurotransmitter levels in preclinical models. As of early 2024, the specific molecular target of CP202 has not been publicly disclosed by the developer.